Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...
TaiMed Biologics (TPEX: 4147) announced that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) ha...
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thal...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Advancement of commercial-ready formulation supports scalability and late-stage development Aspen Neuroscience, Inc., a clinical-stage regenerative medi...
Bavarian Nordic A/S announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikung...
First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 cli...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any pr...
Bayer announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer...
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. Critical...
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) progra...
Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, announced positive ...
© 2026 Biopharma Boardroom. All Rights Reserved.
